Kezar Life Sciences, a small biotech company, closed its operations despite reaching a breakthrough agreement with the FDA for a clinical trial plan in February. The company cited a four-month delay in securing the agreement as a critical factor in its closure, suggesting the timing made the deal commercially unviable.
The case illustrates the precarious financial position many small biotech companies face while navigating regulatory approval processes. These firms often operate with limited cash reserves and tight timelines, making regulatory delays potentially fatal to their operations even when eventual approval is achieved.